Enhancement of radiation response with bevacizumab

Journal of Experimental and Clinical Cancer Research

Volumn 31, Issue 1, 2012, Pages

  Hoang, Tien ^a   Huang, Shyhmin ^a   Armstrong, Eric ^a   Eickhoff, Jens C ^a   Harari, Paul M ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Anti angiogenesis; Bevacizumab; Radiation; VEGF

Indexed keywords

BEVACIZUMAB; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER CELL; CANCER INHIBITION; CAPILLARY; CELL INTERACTION; CELL MOTILITY; CELL PROLIFERATION; CHEMORADIOTHERAPY; CONTROLLED STUDY; ENDOTHELIUM CELL; FLOW CYTOMETRY; GROWTH INHIBITION; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN CELL; LUNG CANCER; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIATION RESPONSE; REVIEW; TREATMENT RESPONSE; TUMOR VASCULARIZATION; TUMOR XENOGRAFT; UMBILICAL VEIN ENDOTHELIAL CELL;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; ENDOTHELIAL CELLS; HEAD AND NECK NEOPLASMS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; LUNG NEOPLASMS; MICE; NEOVASCULARIZATION, PATHOLOGIC; RADIATION-SENSITIZING AGENTS; TRANSPLANTATION, HETEROLOGOUS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84862199559     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-31-37     Document Type: Review

References (24)

1. Tumor angiogenesis: therapeutic implications. Folkman J, N Engl J Med 1971 285 1182 6 10.1056/NEJM197111182852108 4938153
2. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Ferrara N, Henzel WJ, Biochem Biophys Res Commun 1989 161 851 8 10.1016/0006-291X(89)92678-8 2735925 (Pubitemid 19162712)
3. Human vascular permeability factor. Isolation from U937 cells. Connolly DT, Olander JV, Heuvelman D, et al. J Biol Chem 1989 264 20017 24 2584205 (Pubitemid 20008119)
4. VEGF and the quest for tumour angiogenesis factors. Ferrara N, Nat Rev Cancer 2002 2 795 803 10.1038/nrc909 12360282 (Pubitemid 37328914)
5. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Hanahan D, Folkman J, Cell 1996 86 353 64 10.1016/S0092-8674(00) 80108-7 8756718 (Pubitemid 26272076)
6. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Ferrara N, Hillan KJ, Gerber HP, Novotny W, Nat Rev Drug Discov 2004 3 391 400 10.1038/nrd1381 15136787 (Pubitemid 38618122)
7. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Gorski DH, Beckett MA, Jaskowiak NT, et al. Cancer Res 1999 59 3374 8 10416597 (Pubitemid 29334495)
8. Combined effects of angiostatin and ionizing radiation in antitumour therapy. Mauceri HJ, Hanna NN, Beckett MA, et al. Nature 1998 394 287 91 10.1038/28412 9685160 (Pubitemid 28335042)
9. Antitumor interaction of short-course endostatin and ionizing radiation. Hanna NN, Seetharam S, Mauceri HJ, et al. Cancer J 2000 6 287 93 11079167
10. Angiogenesis and radiation response modulation after vascular endothelial growth factor receptor-2 (VEGFR2) blockade. Li J, Huang S, Armstrong EA, Fowler JF, Harari PM, Int J Radiat Oncol Biol Phys 2005 62 1477 85 10.1016/j.ijrobp.2005.04.028 16029810 (Pubitemid 40982073)
11. Augmentation of radiation response with the VEGFR-tyrosine kinase inhibitor ZD6474. Hoang T, Huang S, Armstrong E, Harari PM, Pro Am Assoc Cancer Res 2004 45 955
12. Simultaneous inhibition of the receptor kinase activity of vascular endothelial, fibroblast, and platelet-derived growth factors suppresses tumor growth and enhances tumor radiation response. Griffin RJ, Williams BW, Wild R, Cherrington JM, Park H, Song CW, Cancer Res 2002 62 1702 6 11912143 (Pubitemid 34408492)
13. Impact of adjuvant inhibition of vascular endothelial growth factor receptor tyrosine kinases on tumor growth delay and local tumor control after fractionated irradiation in human squamous cell carcinomas in nude mice. Zips D, Hessel F, Krause M, et al. Int J Radiat Oncol Biol Phys 2005 61 908 14 10.1016/j.ijrobp.2004.11.007 15708274 (Pubitemid 40247990)
14. Enhancement of radiation therapy by the novel vascular targeting agent ZD6126. Siemann DW, Rojiani AM, Int J Radiat Oncol Biol Phys 2002 53 164 71 10.1016/S0360-3016(02)02742-6 12007956 (Pubitemid 34465821)
15. Augmentation of radiation response with the vascular targeting agent ZD6126. Hoang T, Huang S, Armstrong E, Eickhoff JC, Harari PM, Int J Radiat Oncol Biol Phys 2006 64 1458 65 10.1016/j.ijrobp.2005.11.017 16488554
16. Targeting the tumor vasculature with combretastatin A-4 disodium phosphate: effects on radiation therapy. Li L, Rojiani A, Siemann DW, Int J Radiat Oncol Biol Phys 1998 42 899 903 10.1016/S0360-3016(98)00320-4 9845118 (Pubitemid 28559439)
17. Tumor angiogenesis and tissue factor. Folkman J, Nat Med 1996 2 167 8 10.1038/nm0296-167 8574960 (Pubitemid 26054981)
18. Effect of the tumor vascular-damaging agent, ZD6126, on the radioresponse of U87 glioblastoma. Wachsberger PR, Burd R, Marero N, et al. Clin Cancer Res 2005 11 835 42 15701874 (Pubitemid 40116912)
19. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Jain RK, Nat Med 2001 7 987 9 10.1038/nm0901-987 11533692 (Pubitemid 32937367)
20. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Tong RT, Boucher Y, Kozin SV, Winkler F, Hicklin DJ, Jain RK, Cancer Res 2004 64 3731 6 10.1158/0008-5472.CAN-04-0074 15172975 (Pubitemid 38697278)
21. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Willett CG, Boucher Y, di Tomaso E, et al. Nat Med 2004 10 145 7 10.1038/nm988 14745444 (Pubitemid 38524883)
22. Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study. Willett CG, Duda DG, di Tomaso E, et al. J Clin Oncol 2009 27 3020 6 10.1200/JCO.2008.21.1771 19470921
23. Phase I trial evaluating the safety of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer. Crane CH, Ellis LM, Abbruzzese JL, et al. J Clin Oncol 2006 24 1145 51 10.1200/JCO.2005.03.6780 16505434 (Pubitemid 46638812)
24. Phase I study of bevacizumab added to fluorouracil- and hydroxyurea-based concomitant chemoradiotherapy for poor-prognosis head and neck cancer. Seiwert TY, Haraf DJ, Cohen EE, et al. J Clin Oncol 2008 26 1732 41 10.1200/JCO.2007.13. 1706 18375903